Crystal Structures for HIV-1 Reverse Transcriptase in Complexes with Three Pyridinone Derivatives: A New Class of Non-Nucleoside Inhibitors Effective against a Broad Range of Drug-Resistant Strains
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In the treatment of AIDS, the efficacy of all drugs, including non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT), has been limited by the rapid appearance of drug-resistant viruses. Lys103Asn, Tyr181Cys, and Tyr188Leu are some of the most common RT mutations that cause resistance to NNRTIs in the clinic. We report X-ray crystal structures for RT complexed with three different pyridinone derivatives, R157208, R165481, and R221239, at 2.95, 2.9, and 2.43 A resolution, respectively. All three ligands exhibit nanomolar or subnanomolar inhibitory activity against wild-type RT, but varying activities against drug-resistant mutants. R165481 and R221239 differ from most NNRTIs in that binding does not involve significant contacts with Tyr181. These compounds strongly inhibit wild-type HIV-1 RT and drug-resistant variants, including Tyr181Cys and Lys103Asn RT. These properties result in part from an iodine atom on the pyridinone ring of both inhibitors that interacts with the main-chain carbonyl oxygen of Tyr188. An acrylonitrile substituent on R165481 substantially improves the activity of the compound against wild-type RT (and several mutants) and provides a way to generate novel inhibitors that could interact with conserved elements of HIV-1 RT at the polymerase catalytic site. In R221239, there is a flexible linker to a furan ring that permits interactions with Val106, Phe227, and Pro236. These contacts appear to enhance the inhibitory activity of R221239 against the HIV-1 strains that carry the Val106Ala, Tyr188Leu, and Phe227Cys mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115
Self-citation
Cited by
Cavallo, G., Metrangolo, P., Milani, R., Pilati, T., Priimagi, A., Resnati, G., & Terraneo, G. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00484 · Cited by 4,035
A Medicinal Chemist’s Guide to Molecular Interactions
Bissantz, C., Kuhn, B., & Stahl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100112j · Cited by 1,731
Halogen Bonding in Supramolecular Chemistry
Gilday, L. C., Robinson, S. W., Barendt, T. A., Langton, M. J., Mullaney, B. R., & Beer, P. D. (2015) · Chemical Reviews · doi:10.1021/cr500674c · Cited by 1,339
Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology
Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C., & Boeckler, F. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3012068 · Cited by 1,331
Halogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
Computer Modeling of Halogen Bonds and Other σ-Hole Interactions
Kolář, M. H., & Hobza, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00560 · Cited by 660
Halogen Bonding—A Novel Interaction for Rational Drug Design?
Lu, Y., Shi, T., Wang, Y., Yang, H., Yan, X., Luo, X., Jiang, H., & Zhu, W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9000133 · Cited by 559
Halogen bonding in halocarbon–protein complexes: a structural survey
Parisini, E., Metrangolo, P., Pilati, T., Resnati, G., & Terraneo, G. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00177e · Cited by 443
Halogen Bond: Its Role beyond Drug–Target Binding Affinity for Drug Discovery and Development
Xu, Z., Yang, Z., Liu, Y., Lu, Y., Chen, K., & Zhu, W. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400539q · Cited by 431
Riley, K. E., & Hobza, P. (2008) · Journal of Chemical Theory and Computation · doi:10.1021/ct700216w · Cited by 428
Lu, Y., Wang, Y., & Zhu, W. (2010) · Physical Chemistry Chemical Physics · doi:10.1039/b926326h · Cited by 394
Das, K., Bauman, J. D., Clark, A. D., Frenkel, Y. V., Lewi, P. J., Shatkin, A. J., Hughes, S. H., & Arnold, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711209105 · Cited by 343
Self-citationHalogen bonding for rational drug design and new drug discovery
Lu, Y., Liu, Y., Xu, Z., Li, H., Liu, H., & Zhu, W. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.678829 · Cited by 318
Treatment of Halogen Bonding in the OPLS-AA Force Field: Application to Potent Anti-HIV Agents
Jorgensen, W. L., & Schyman, P. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300180w · Cited by 262
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
A quantum mechanics-based halogen bonding scoring function for protein-ligand interactions.
Yang, Z., Liu, Y., Chen, Z., Xu, Z., Shi, J., Chen, K., & Zhu, W. (2015) · Journal of Molecular Modeling · doi:10.1007/s00894-015-2681-6 · Cited by 23
Metadata
- Authors
- Himmel, D. M., Das, K., Clark, Hughes, S. H., Benjahad, A., Oumouch, S., Guillemont, J., Coupa, S., Poncelet, A., Csoka, I., Meyer, C., Andries, K., Nguyen, C. H., Grierson, D. S., & Arnold, E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-11-02
- Volume
- 48
- Issue
- 24
- Pages
- 7582-7591
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1999577669
- Cited by
- 139
- References
- 2
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.